Covalon Technologies (COV) Q4 2025 earnings summary

Executive summary

• Achieved highest quarterly revenue of fiscal 2025 in Q4, with $8.7 million, marking the third consecutive year of revenue growth and essentially flat year-over-year.

• Full-year revenue reached $32.8 million, up 5.3% from the prior year, driven by strong growth in U.S. vascular access, surgical, and international channels.

• Added 74 new U.S. hospital customers and retained 100% of top 50 hospital accounts, with 25% revenue growth from these key customers.

• Issued a special dividend of $0.15 per share, the first in company history, totaling $4.1 million.

• Ended the year with $17 million in cash and no debt, maintaining seven consecutive profitable quarters.

Financial highlights

• Q4 revenue was $8.7 million, highest of the year but down 2% year-over-year.

• Full-year revenue grew 5.3% to $32.8 million; 3-year CAGR of 25.6%.

• Gross margin for the year was 53% (56% excluding inventory write-offs), down from 61% prior year.

• Operating expenses decreased by 6.4% year-over-year to $15.7 million.

• Adjusted EBITDA for the year was $3.7 million, with diluted EPS of $0.07.

Outlook and guidance

• Management expects growth acceleration in FY'26 and beyond, focusing on commercial advancement, market development, and innovation.

• Recently secured a new U.S. strategic partner with a $1 million order to be delivered in Q2 FY'26.

• Gross margins expected to remain in the low-to-high 50% range, potentially reaching low 60% for med tech peers.

• Disruption from a U.S. advanced wound care partner's ownership transition is not expected to persist long-term.